P/80/2010 - paediatric investigation plan

Taspoglutide

Key facts

• Active Substance:
  Taspoglutide
• Therapeutic area:
  Endocrinology-Gynaecology-Fertility-Metabolism
• Decision number:
  P/80/2010
• PIP number:
  P/80/2010
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of type II diabetes mellitus
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Ipsen Pharma

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  07/05/2010

Decision

P/80/2010: European Medicines Agency decision of 7 May 2010 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for taspoglutide (EMEA-000649-PIP01-09) i...

AdoptedReference Number: EMA/265545/2010